New updates have been reported about CraniUS Therapeutics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CraniUS Therapeutics has strengthened its board by appointing Oray B. Boston Jr., a former senior Johnson & Johnson executive with more than three decades of global leadership in medical devices and pharmaceuticals, as a director. Boston previously led DePuy Synthes’ worldwide Trauma, Extremities, Craniomaxillofacial, Sports and Animal Health portfolio, giving him direct experience in cranial implants, commercialization strategy, and operational execution across developed and emerging markets.
His background includes serving as President of Global Biosurgery at Ethicon, where he oversaw large-scale product launches, international expansion, and commercial organization building in highly regulated healthcare environments; he currently sits on the board of Keurig Dr Pepper. CraniUS leadership expects his expertise to support the company’s progression from development to clinical validation and ultimately toward commercialization of NeuroPASS™, its fully implantable, skull-embedded drug delivery platform designed to bypass the blood–brain barrier for localized treatment of neurological disease.
Boston said he plans to help guide CraniUS as it advances a differentiated neurotechnology approach through upcoming clinical and commercial milestones, signaling increased board-level focus on go-to-market planning and potential partnering strategies. Founder and Executive Chairman Dr. Chad Gordon highlighted that Boston’s track record in craniofacial device innovation and global implant launches aligns directly with the company’s needs as it scales its multi-product platform and navigates regulatory pathways.
Chief Executive Officer Mike Maglin emphasized that Boston’s combined experience in both cranial devices and pharmaceutical platforms should sharpen the board’s ability to shape near-term commercialization strategies and position CraniUS for growth opportunities in the neurotechnology sector. The Baltimore-based company is developing NeuroPASS™ as a long-term, programmable delivery system intended to transform treatment options across multiple neurological indications, and it collaborates with global experts in neurosurgery, drug delivery, implant design, engineering, and manufacturing to support eventual market entry.
The appointment indicates that CraniUS is entering a more execution-oriented phase, where board composition is being aligned with anticipated clinical trial activity, regulatory engagement, and eventual scale-up requirements. For investors and strategic partners, Boston’s addition suggests CraniUS is preparing for capital-intensive steps tied to clinical development and early commercialization, while positioning its platform to compete in an emerging market for targeted, implantable drug delivery solutions for the brain.